IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1375.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 8-Jun-2015
SNMMI 2015 Annual Meeting
Follow-up PET/CT more than 95 percent sensitive for non-Hodgkin lymphoma
Non-Hodgkin lymphoma, a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive. For more aggressive cases, post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment, say researchers presenting during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 8-Jun-2015
American Journal of Pathology
'Genomic catastrophe' may cause normal cells to become cancerous
A new study published in the American Journal of Pathology provides the missing link between a single untoward event, cell fusion, and the multiple catastrophic genetic changes that ultimately transform normal cells into cancerous cells. Furthermore, when injected into live animals, these aberrant cells form tumors.
National Institutues of Health, University of Michigan Comprehensive Cancer Center

Contact: Eileen Leahy
ajpmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 8-Jun-2015
SNMMI 2015 Annual Meeting
Dynamic whole-body PET detects more cancer
Imaging lung cancer requires both precision and innovation. With this aim, researchers have developed a technique for clinical positron emission tomography (PET) imaging that creates advanced whole-body parametric maps, which allow quantitative evaluation of tumors and metastases throughout the body, according to research announced at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
Massachusetts General Hospital

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 8-Jun-2015
SNMMI 2015 Annual Meeting
PET detects more prostate cancer than conventional imaging
Research presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging shows how a new molecular imaging agent finds prostate cancer that has spread to other tissues by locking in on an enzyme called prostate specific membrane antigen, associated with prostate cancer.
ImaginAb Inc.

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 8-Jun-2015
SNMMI 2015 Annual Meeting
Theranostic PET takes on both ovarian and prostate cancer
A first-in-human study revealed at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment.
Avipep Pty Ltd.

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 8-Jun-2015
SNMMI 2015 Annual Meeting
PET/CT captures hidden source of neuroendocrine cancer
The origin of cancer is often obscured by metastases -- tumors that have already spread to other tissues. This is especially the case for neuroendocrine tumors, a malignancy of nerve cells scattered throughout various organ systems that are sensitive to the signaling of neurotransmitters and hormones. An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
NIH/National Institute of Neurological Disorders and Stroke

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 8-Jun-2015
SNMMI 2015 Annual Meeting
Molecular MRI aims at component of multiple cancers
A relatively new biomarker called prostate-specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Johns Hopkins University, National Institutes of Health

Contact: Laurie Callahan
lcallahan@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 7-Jun-2015
Philosophical Transactions of the Royal Society B
New study describes cancer's cheating ways
In a new study, Athena Aktipis, a researcher at Arizona State University's Biodesign Institute, along with her international colleagues, explore the ways in which cancers bypass the protective mechanisms used by multicellular forms to ensure their survival and well-being.

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University

Public Release: 5-Jun-2015
European Society of Human Genetics Conference
JAMA Oncology
Noninvasive prenatal fetal testing can detect early stage cancer in mothers
Noninvasive prenatal testing (NIPT) for chromosomal fetal disorders is used increasingly to test for conditions such as Down's syndrome, because it is known to be much safer than invasive testing methods. Now, for the first time, researchers from Belgium have found another advantage of NIPT; it can detect maternal cancers at an early stage, before symptoms appear.
University of Leuven, Belgian Cancer Plan, Belgian Science Policy Office

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society of Human Genetics

Public Release: 5-Jun-2015
Blood
Rabbit virus improves bone marrow transplants, kills some cancer cells
University of Florida Health researchers have discovered that a rabbit virus can deliver a one-two punch, killing some kinds of cancer cells while eliminating a common and dangerous complication of bone marrow transplants.
Florida Bankhead-Coley Cancer Research Program, NIH/National Cancer Institute

Contact: Doug Bennett
dougbennett@ufl.edu
352-273-5706
University of Florida

Public Release: 5-Jun-2015
PLOS ONE
Fruit fly genetics reveal pesticide resistance and insight into cancer
Thomas Werner at Michigan Technological University has bridged the miniscule and the massive in an effort to better understand the mechanisms behind several unique features of fruit fly genes.
National Science Foundation

Contact: Thomas Werner
twerner@mtu.edu
906-487-1209
Michigan Technological University

Public Release: 4-Jun-2015
Cancer
Cancer screening increase may reflect Affordable Care Act provision
Screening for colorectal cancer increased in lower socioeconomic status individuals after 2008, perhaps reflecting the Affordable Care Act's removal of financial barriers to screening according to a new analysis.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 4-Jun-2015
Current Biology
Forks colliding: How DNA breaks during re-replication
Leveraging a novel system designed to examine the double-strand DNA breaks that occur as a consequence of gene amplification during DNA replication, Whitehead Institute scientists are bringing new clarity to the causes of such genomic damage. Moreover, because errors arising during DNA replication and gene amplification result in chromosomal abnormalities often found in malignant cells, these new findings may bolster our understandings of certain drivers of cancer progression.
National Institutes of Health, MIT School of Science Fellowship in Cancer Research

Contact: Matt Fearer
fearer@wi.mit.edu
617-452-4630
Whitehead Institute for Biomedical Research

Public Release: 4-Jun-2015
JAMA Otolaryngology - Head & Neck Surgery
What are Medicare costs for patients with oral cavity, pharyngeal cancers?
Medicare costs for older patients with oral cavity and pharyngeal cancers increased based on demographics, co-existing illnesses and treatment selection, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.

Contact: Matthew G. Solovey
msolovey@hmc.psu.edu
717-531-0003 x287127
The JAMA Network Journals

Public Release: 4-Jun-2015
Journal of Clinical Endocrinology and Metabolism
Panel recommends improvements in estrogen testing accuracy
Unreliable estrogen measurements have had a negative impact on the treatment of and research into many hormone-related cancers and chronic conditions. To improve patient care, a panel of medical experts has called for accurate, standardized estrogen testing methods in a statement published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
202-971-3655
The Endocrine Society

Public Release: 4-Jun-2015
International Journal of Data Mining and Bioinformatics
Social networking against cancer
Research published in International Journal of Data Mining and Bioinformatics shows how social network analysis can be used to understand and identify the biomarkers in our bodies for diseases, including different types of cancer.

Contact: Albert Ang
press@inderscience.com
Inderscience Publishers

Public Release: 4-Jun-2015
Cancer Discovery
An immune system marker for therapy-resistant prostate cancer
A team at CSHL shows how signaling by an immune system component called interleukin-6 (IL-6) appears to play an important role in driving aggressive, therapy-resistant prostate cancer. 'We are hopeful that translating the IL-6 discovery into the clinics could help us stratify patients into good responders and bad responders. For any hospital this would be a major breakthrough,' says PI Dr. Lloyd Trotman.
Pershing Square Sohn Cancer Research Alliance, American Cancer Society, National Institutes of Health, US Department of Defense, STARR Foundation

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory

Public Release: 3-Jun-2015
Cell Reports
Cytoskeletons shaking hands
For the fist time it is shown that specific contractile actin filament structures called arcs functionally interact with cytoplasmic intermediate filaments.

Contact: Pekka Lappalainen
pekka.lappalainen@helsinki.fi
358-504-155-433
University of Helsinki

Public Release: 3-Jun-2015
Scientific Reports
Intravenous nutrition source could reduce side effects of chemotherapy
A single dose of an FDA-approved intravenous nutrition source may be able to significantly reduce the toxicity and increase the bioavailability of platinum-based cancer drugs, according to a study by Carnegie Mellon University biologists published in Scientific Reports.
National Institutes of Health, Carnegie Mellon University's Disruptive Health Technology Institute

Contact: Jocelyn Duffy
jhduffy@andrew.cmu.edu
412-268-9982
Carnegie Mellon University

Public Release: 3-Jun-2015
2015 ASCO Annual Conference
Study supports IDH gene as prognostic marker in anaplastic astrocytoma
A new study suggests that the mutation status of a gene called IDH1 might have prognostic value for anaplastic astrocytomas, and that it may be worth exploring further whether IDH1 status can predict the best chemotherapy for these patients.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 3-Jun-2015
Science Signaling
Triple treatment keeps cancer from coming back
According to new research by the Weizmann Institute's Professor Yosef Yarden, a new strategy involving a three-pronged approach might keep an aggressive form of lung cancer from returning.

Contact: Yael Edelman
yael.edelman@weizmann.ac.il
Weizmann Institute of Science

Public Release: 3-Jun-2015
eLife
Cause or consequence? John Innes Centre scientists help to settle an epigenetic debate
Using the flowering plant Arabidopsis thaliana as a model for their research, Professor Martin Howard, Professor Caroline Dean and members of their labs, have been trying to understand how organisms 'remember' past events at the cellular level.
The European Research Council, The Biotechnology and Biological Sciences Research Council, The John Innes Foundation

Contact: Geraldine Platten
geraldine.platten@jic.ac.uk
01-603-450-238
Norwich BioScience Institutes

Public Release: 3-Jun-2015
Journal of Experimental Medicine
Penn researchers home in on what's wearing out T cells
When the T cells of your immune system are forced to deal over time with cancer or a chronic infection they become exhausted -- less effective at attacking and destroying invaders. While the PD-1 protein pathway has long been implicated as a primary player in T cell exhaustion, a major question has been whether PD-1 actually directly causes exhaustion. A new paper seems to, at least partially, let PD-1 off the hook.
Robertson Foundation/Cancer Research Institute and the National Institutes of Health

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 3-Jun-2015
Nucleic Acid Therapeutics
New aptamer-based approach delivers microRNA therapeutic that targets cancer/cardiovascular disease
Researchers have shown that a novel delivery strategy can efficiently introduce a functional microRNA that has anti-cancer and angiogenic activities into two different types of cells--breast cancer cells to inhibit tumor growth and metastasis, and cells that line blood vessels to protect against atherosclerosis. The overexpression of miR-126 using a universal aptamer delivery approach is described in an article in Nucleic Acid Therapeutics.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 3-Jun-2015
Oncotarget
Wistar scientists discover 'highly effective' new biomarker for lung cancer
Scientists at The Wistar Institute have found a protein that circulates in the blood that appears to be more accurate at detecting non-small cell lung cancer than currently available methods used for screening.
Pennsylvania Department of Health, W.W. Smith Foundation, Breast Cancer Alliance, Edward Mallinckrodt Jr. Foundation, Doctor's Cancer Foundation

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Showing releases 176-200 out of 1375.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

  Search News Releases

     

 

EurekAlert!